Commercial variants of the prothrombin time test as a screening test of acquired coagulation factor II, VII, and X deficiencies in dogs.
The aim of this study was to acquire the single factor sensitivity of three commercial variants of the prothrombin time test (PT(Va1)-Thrombotest, PT(Va2)-Normotest, PT(Va3)-Hepato Quick) for canine plasma. For this purpose, 38 samples from animals with coumarin intoxication followed by vitamin K(1) treatment who had a reduced activity of the coagulation factors II, VII, and/or X (experiment 1) as well as 25 plasma samples from animals with moderately reduced activity of the coagulation factors II, V, VII, and/or X caused by a hepatogenic synthesis disorder or disseminated intravascular coagulation (experiment 2), were examined. Measurements for all tests were performed according to the instructions of the manufacturer and also with higher plasma dilution. Furthermore, control measurements were performed with the conventional prothrombin time test (standard test; PT(ST)). The prothrombin time measured with the PT(Va3), which was prolonged in all samples from experiments 1 and 2, especially reflected with high sensitivity the reduced activity of the coagulation factors. The measurements with PT(Va2) and PT(Va1) showed only an insignificantly lower sensitivity (> or =0.88) with a maximum of 1 (experiment 1) and 3 (experiment 2) false negative test results, respectively. Compared to the already high sensitivity, a higher dilution of the sample material did not lead to a significantly higher sensitivity (P>0.05) for any of the tested commercial variants of the prothrombin time assay. While there was no significant difference (P>0.05) between the number of false negative test results in the variants of the prothrombin time assay, in both experiments a significantly higher number of false negative test results was found for the PT(ST) (P<0.001). The results show that, in contrast to the PT(ST), all three tested commercial prothrombin time variants are suitable for the detection of deficiencies of coagulation factors II, VII, and X in canine plasma.
Mischke
R
R
Clinic for Small Animals, School of Veterinary Medicine, Bischofsholer Damm 15, D-30173 Hannover, Germany. reinhard.mischke@tiho-hannover.de
D000818:Animals; D020147:Coagulation Protein Disorders / Q000097:blood / Q000175:diagnosis* / Q000662:veterinary*; D004283:Dog Diseases / Q000097:blood / Q000175:diagnosis*; D004285:Dogs; D005167:Factor VII / Q000032:analysis; D005170:Factor X / Q000032:analysis; D005260:Female; D008297:Male; D008403:Mass Screening / Q000379:methods* / Q000662:veterinary*; D011516:Prothrombin / Q000032:analysis; D011517:Prothrombin Time; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D013918:Thrombin Time
D011933:Reagent Kits, Diagnostic; D005167:Factor VII; D011516:Prothrombin; D005170:Factor X